Your browser is no longer supported. Please, upgrade your browser.
Nymox Pharmaceutical Corporation
Index- P/E- EPS (ttm)-0.16 Insider Own4.50% Shs Outstand81.49M Perf Week-7.80%
Market Cap164.51M Forward P/E- EPS next Y- Insider Trans1.14% Shs Float38.30M Perf Month-1.56%
Income-12.60M PEG- EPS next Q- Inst Own2.50% Short Float6.92% Perf Quarter29.45%
Sales0.00M P/S- EPS this Y16.80% Inst Trans-61.60% Short Ratio7.89 Perf Half Y-26.74%
Book/sh0.06 P/B31.50 EPS next Y- ROA-277.10% Target Price- Perf Year-20.25%
Cash/sh0.07 P/C26.53 EPS next 5Y- ROE-472.20% 52W Range1.25 - 3.50 Perf YTD-23.79%
Dividend- P/FCF- EPS past 5Y19.80% ROI- 52W High-46.00% Beta1.55
Dividend %- Quick Ratio3.80 Sales past 5Y- Gross Margin- 52W Low51.02% ATR0.15
Employees3 Current Ratio3.80 Sales Q/Q- Oper. Margin- RSI (14)46.08 Volatility8.35% 6.92%
OptionableYes Debt/Eq0.06 EPS Q/Q-19.40% Profit Margin- Rel Volume0.80 Prev Close2.09
ShortableYes LT Debt/Eq0.06 Earnings- Payout- Avg Volume335.89K Price1.89
Recom- SMA20-8.94% SMA508.64% SMA200-10.34% Volume268,940 Change-9.57%
Feb-15-11Initiated BioLogic Equity Research Sell
Sep-10-21 09:30AM  
Jul-27-21 03:58AM  
May-06-21 01:30PM  
Apr-28-21 08:30AM  
Mar-29-21 09:20AM  
Nov-16-20 10:00AM  
Nov-03-20 08:43AM  
Aug-12-20 09:24AM  
Jul-28-20 09:30AM  
Jun-19-20 09:30AM  
Jun-05-20 03:16PM  
May-05-20 09:08AM  
Apr-21-20 09:45AM  
Mar-21-20 10:10AM  
Feb-24-20 09:30AM  
Feb-06-20 09:30AM  
Feb-05-20 10:32AM  
Jan-28-20 09:30AM  
Jan-07-20 07:57AM  
Jan-06-20 11:00AM  
Dec-23-19 03:58PM  
Dec-20-19 08:04AM  
Nov-05-19 09:35AM  
Oct-21-19 09:30AM  
Jul-24-19 11:58AM  
Jul-08-19 12:16PM  
Jun-25-19 11:45AM  
Jun-18-19 03:20PM  
May-15-19 04:03PM  
May-10-19 11:24AM  
Apr-16-19 12:46PM  
Mar-21-19 01:45PM  
Mar-19-19 09:45AM  
Mar-18-19 12:15PM  
Mar-13-19 09:30AM  
Mar-11-19 11:53AM  
Jan-30-19 01:40PM  
Jan-15-19 10:45AM  
Dec-19-18 10:30AM  
Dec-14-18 02:51PM  
Nov-13-18 07:29PM  
Oct-11-18 10:45AM  
Oct-09-18 10:00AM  
Oct-03-18 11:46AM  
Aug-13-18 06:35PM  
Jul-02-18 09:30AM  
Jun-07-18 09:30AM  
May-22-18 10:00AM  
May-16-18 05:05AM  
May-11-18 09:30AM  
May-07-18 09:00AM  
May-02-18 09:30AM  
May-01-18 03:14PM  
Apr-13-18 05:19PM  
Apr-12-18 09:45AM  
Apr-10-18 10:00AM  
Mar-19-18 10:46AM  
Mar-01-18 09:30AM  
Feb-27-18 07:27PM  
Feb-05-18 11:15AM  
Jan-30-18 09:30AM  
Jan-22-18 11:30AM  
Dec-22-17 11:46AM  
Dec-11-17 02:04PM  
Nov-30-17 02:12PM  
Nov-29-17 07:45AM  
Nov-27-17 11:00AM  
Nov-16-17 11:10AM  
Nov-10-17 10:30AM  
Nov-07-17 11:15AM  
Oct-26-17 08:40PM  
Oct-13-17 09:37AM  
Oct-10-17 10:00AM  
Sep-25-17 10:30AM  
Sep-14-17 12:40PM  
Sep-12-17 12:13AM  
Sep-11-17 12:15PM  
Aug-31-17 07:47PM  
Aug-24-17 10:42AM  
Aug-09-17 10:30AM  
Aug-07-17 10:00AM  
Aug-03-17 08:58PM  
Jul-04-17 03:16PM  
May-31-17 10:00AM  
May-24-17 10:01AM  
May-16-17 05:02AM  
May-10-17 11:15AM  
May-08-17 11:00AM  
May-03-17 09:30AM  
Apr-05-17 08:47AM  
Mar-30-17 09:30AM  
Mar-29-17 10:45AM  
Nov-29-16 09:45AM  
Oct-12-16 10:10AM  
Oct-11-16 12:05PM  
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, The Bahamas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Robinson James GeorgeDirectorApr 22Buy2.0827,00056,2153,550,550Apr 27 11:09 AM
Robinson James GeorgeDirectorApr 21Buy2.0813,00027,0583,523,550Apr 27 11:09 AM